Q-omics provides the consensus-scored SUCNR1 profile across patient tissues and cancer cell-line models. SUCNR1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SUCNR1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SUCNR1 RNA expression shows 17,022 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where SUCNR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUCNR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUCNR1 survival associations across molecular data types. SUCNR1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUCNR1 RNA expression–survival associations across cancer types. High SUCNR1 expression shows unfavorable associations in KIRP and UVM, but favorable associations in SKCM, ACC, HNSC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SUCNR1 RNA expression.
This table summarizes SUCNR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SUCNR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUCNR1 shows lower tumor expression in KIRC, KIRP, THCA and LUSC and higher tumor expression in HNSC and COAD. The KIRC box plot shows higher SUCNR1 RNA expression in normal versus tumor tissue (log2 FC = −2.505, t-test p < 0.001).
This table shows molecular features associated with SUCNR1 in patient tissues and cancer cell lines. In patient samples, SUCNR1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SUCNR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
